

## Curis to Present at the Oppenheimer 24th Annual Healthcare Conference

LEXINGTON, Mass., Dec. 4, 2013 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused drug development company seeking to develop novel drug candidates for the treatment of human cancers, today announced that the Company will present at the Oppenheimer 24<sup>th</sup> Annual Healthcare Conference at 2:45 p.m. ET on December 11, 2013, in New York City.

Dan Passeri, Chief Executive Officer, will provide an overview of Curis' proprietary cancer programs including its antagonist of inhibitor of apoptosis (IAP) proteins, CUDC-427, and its dual target phosphoinositide 3-kinase (PI3K) and histone deacetylase (HDAC) inhibitor, CUDC-907. Mr. Passeri will also provide an overview of Curis' partnered programs including Erivedge® (vismodegib), a hedgehog pathway inhibitor developed under collaboration with Genentech/ Roche that is the first and only approved medicine for patients with advanced basal cell carcinoma, and HSP90 inhibitor, Debio 0932 that is in clinical development by Curis' collaborator Debiopharm.

A corresponding webcast of the presentation can be accessed by visiting:

<http://www.veracast.com/webcasts/opco/healthcare2013/24212349971.cfm>

The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at [www.curis.com](http://www.curis.com).

### About Curis, Inc.

Curis is an oncology-focused drug development company seeking to develop and commercialize next generation targeted small molecule drug candidates for cancer treatment. Erivedge® is the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma and is being commercialized and developed by Roche and Genentech, a member of the Roche Group, under a collaboration agreement between Curis and Genentech. Curis is also leveraging its experience in targeting signaling pathways to develop proprietary targeted cancer programs, including CUDC-427, a small molecule antagonist of IAP proteins, and CUDC-907, a dual PI3K and HDAC inhibitor. For more information, visit Curis' website at [www.curis.com](http://www.curis.com).

CONTACT: Mani Mohindru, Ph.D.

Vice President, Corporate Strategy and Investor Relations

617-503-6605

[mmohindru@curis.com](mailto:mmohindru@curis.com)

Michael P. Gray

Chief Financial Officer

Curis, Inc.

617-503-6632

[mgray@curis.com](mailto:mgray@curis.com)

---

<https://investors.curis.com/Curis-to-Present-at-the-Oppenheimer-24th-Annual-Healthcare-Conference>